In April, just 12 weeks into her pregnancy, Kathleen Clark was standing at the receptionist window of her OB-GYN’s office when she was asked to pay $960, the total the office estimated she would owe after she delivered. Clark, 39, was shocked that she was asked to pay that amount during this second prenatal visit….
Alkermes is chasing Takeda Pharmaceutical, whose orexin receptor-targeting pill is on track to become first in a new class of narcolepsy medicines. Blair Jackson, chief operating officer of the neuroscience biotech, says Alkermes’s drug offers advantages and also paves the way to bring orexin agonism to other indications. The post Neuroscience Biotech Alkermes Sees Narcolepsy…
Foreigners seeking visas to live in the U.S. might be rejected if they have certain medical conditions, including diabetes or obesity, under a Thursday directive from the Trump administration. The guidance, issued in a cable the State Department sent to embassy and consular officials and examined by KFF Health News, directs visa officers to deem…
Novo Holdings led the Series A investment in Kivu Biosciences, developer of next-generation antibody drug conjugates for solid tumors. The startup’s ADCs and technology were licensed from Synaffix, a Lonza subsidiary. The post Precision Oncology Startup Kivu Unveils $92M for More Stable & Durable ADC Cancer Drugs appeared first on MedCity News.
Romvimza, a drug for treating tenosynovial giant cell tumor, was initially developed by Deciphera Pharmaceuticals. Last year, Ono Pharmaceutical acquired Deciphera to build up its oncology portfolio and expand its business prospects in the U.S. and Europe. The post Ono Pharma Drug Acquired in $2.4B Deal Wins FDA Approval for Treating Rare Type of Tumor…
Lumeris says ‘Tom’ platform to enable tracking, performance management, and scalable best-next-action workflows embedded in clinical operations
This guide provides an overview of executive orders and other executive actions made by the Trump Administration since January 21, 2025 that directly address or affect U.S. global health efforts. This resource identifies each executive action, describes its purpose and actions taken, and outlines the implications and what happens next for each. The resource will…
Apellis Pharmaceuticals and Astellas Pharma have the first two FDA-approved therapies for geographic atrophy, but Character Biosciences claims its approach could be best in class for treating this advanced form of dry age-related macular degeneration. The biotech’s Series B round will finance clinical tests of two programs, each addressing a different stage of the disease….
A cancer patient might live in a town with four oncology groups, but only one accepts his insurance — the one owned by his insurer. A young couple could see huge bills after their child is born, because their insurer agreed to the health system’s rates in exchange for a contract with obstetricians across the…
A next-generation Vertex Pharmaceuticals pain drug failed to beat a placebo in a Phase 2 clinical trial. Despite the disappointing outcome in bunionectomy pain, the company is continuing development of the oral drug in diabetic peripheral neuropathy. The post Vertex Non-Opioid Pain Drug Flunks Proof-of-Concept Test, Ending Plans for a Pivotal Study appeared first on…